Cellectar's $140M raise sets NDA clock for iopofosine I 131

An oversubscribed $140 million financing positions Cellectar Biosciences to file an NDA under the accelerated approval pathway for iopofosine I 131 in Waldenström macroglobulinemia, a sequence that compresses CMC readiness, process validation, and confirmatory study timelines into a single capital deployment window.

Cellectar closes $140M raise for iopofosine NDA filing

The financing, announced 5 May 2026, is structured as approximately $35 million upfront and $105 million in milestone-based securities, issued through a registered direct offering of common stock and a concurrent private placement of common stock, pre-funded warrants, and milestone-based warrants. Nantahala Capital Management led the round, with participation from Balyasny Asset Management, Caligan Partners, Janus Henderson Investors, SilverArc Capital Management, Stonepine Capital Management, Empery Asset Management LP, and StemPoint Capital LP, among other dedicated healthcare funds.

The capital is earmarked to support an NDA submission targeting accelerated approval in the US and conditional marketing approval in Europe, alongside initiation of a global confirmatory study planned for Q4 2026. Iopofosine I 131 is a radiopharmaceutical built on Cellectar's Phospholipid Drug Conjugate platform, and the program has generated clinical evidence across multiple Phase 2 studies in the Waldenström macroglobulinemia population.

The CMC and manufacturing read for radiopharmaceutical teams

For CMC leads and QA directors overseeing radiopharmaceutical programs, the accelerated approval route introduces a compressed but well-defined regulatory sequence. An NDA filed under 21 CFR Part 314 Subpart H requires the same chemistry, manufacturing, and controls package as a standard submission, process validation data, sterility assurance documentation, and container-closure integrity evidence must be submission-ready before the NDA clock starts.

The milestone-based tranche structure is relevant here: manufacturing scale-up and analytical method validation expenditures will need to align with milestone triggers, not a single upfront capital release. QA and regulatory affairs leads should map ICH Q10 pharmaceutical quality system requirements against the milestone schedule to avoid gaps between funding availability and GMP compliance obligations at the confirmatory study sites.

Q4 2026 confirmatory study launch is the near-term checkpoint

The confirmatory study initiation, targeted for Q4 2026, is the first operational marker against which manufacturing readiness will be measured. Global study sites will require validated drug supply chains and site-specific GMP documentation before first patient dosing. Andrew Gu of Nantahala Capital Management joins Cellectar's Board of Directors upon closing of the transaction, adding investor-level oversight to the development timeline.

Cellectar also indicated that proceeds will support advancement of CLR 125, an Auger-emitting program in triple-negative breast cancer, though the NDA filing for iopofosine I 131 remains the primary near-term regulatory milestone.

The NDA submission timeline has not been publicly specified beyond the confirmatory study start date, making Q4 2026 the measurable checkpoint for assessing whether manufacturing and CMC workstreams are tracking to plan.